Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

Cited In for PubMed (Select 20139980)

1.

Phosphorylation of Dok1 by Abl family kinases inhibits CrkI transforming activity.

Ng KY, Yin T, Machida K, Wu YI, Mayer BJ.

Oncogene. 2014 Jul 21. doi: 10.1038/onc.2014.210. [Epub ahead of print]

PMID:
25043303
2.

mRNA expression of DOK1-6 in human breast cancer.

Ghanem T, Bracken J, Kasem A, Jiang WG, Mokbel K.

World J Clin Oncol. 2014 May 10;5(2):156-63. doi: 10.5306/wjco.v5.i2.156.

3.

Epstein-Barr virus down-regulates tumor suppressor DOK1 expression.

Siouda M, Frecha C, Accardi R, Yue J, Cuenin C, Gruffat H, Manet E, Herceg Z, Sylla BS, Tommasino M.

PLoS Pathog. 2014 May 8;10(5):e1004125. doi: 10.1371/journal.ppat.1004125. eCollection 2014 May.

4.

EgoNet: identification of human disease ego-network modules.

Yang R, Bai Y, Qin Z, Yu T.

BMC Genomics. 2014 Apr 28;15:314. doi: 10.1186/1471-2164-15-314.

5.

SNP rs10248565 in HDAC9 as a novel genomic aberration biomarker of lung adenocarcinoma in non-smoking women.

Lai LC, Tsai MH, Chen PC, Chen LH, Hsiao JH, Chen SK, Lu TP, Lee JM, Hsu CP, Hsiao CK, Chuang EY.

J Biomed Sci. 2014 Mar 21;21:24. doi: 10.1186/1423-0127-21-24.

6.

BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.

Miah S, Goel RK, Dai C, Kalra N, Beaton-Brown E, Bagu ET, Bonham K, Lukong KE.

PLoS One. 2014 Feb 11;9(2):e87684. doi: 10.1371/journal.pone.0087684. eCollection 2014. Erratum in: PLoS One. 2014;9(5):e98814.

7.

DOK2 inhibits EGFR-mutated lung adenocarcinoma.

Berger AH, Chen M, Morotti A, Janas JA, Niki M, Bronson RT, Taylor BS, Ladanyi M, Van Aelst L, Politi K, Varmus HE, Pandolfi PP.

PLoS One. 2013 Nov 8;8(11):e79526. doi: 10.1371/journal.pone.0079526. eCollection 2013.

8.

A physical interaction between the adaptor proteins DOK3 and DAP12 is required to inhibit lipopolysaccharide signaling in macrophages.

Peng Q, Long CL, Malhotra S, Humphrey MB.

Sci Signal. 2013 Aug 20;6(289):ra72. doi: 10.1126/scisignal.2003801.

9.

Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy.

Chen YC, Hsiao CC, Chen KD, Hung YC, Wu CY, Lie CH, Liu SF, Sung MT, Chen CJ, Wang TY, Chang JC, Tang P, Fang WF, Wang YH, Chung YH, Chao TY, Leung SY, Su MC, Wang CC, Lin MC.

PLoS One. 2013;8(2):e57053. doi: 10.1371/journal.pone.0057053. Epub 2013 Feb 25.

10.

The Dok-3/Grb2 protein signal module attenuates Lyn kinase-dependent activation of Syk kinase in B cell antigen receptor microclusters.

Lösing M, Goldbeck I, Manno B, Oellerich T, Schnyder T, Bohnenberger H, Stork B, Urlaub H, Batista FD, Wienands J, Engelke M.

J Biol Chem. 2013 Jan 25;288(4):2303-13. doi: 10.1074/jbc.M112.406546. Epub 2012 Dec 5.

11.
12.

Transcriptional regulation of the human tumor suppressor DOK1 by E2F1.

Siouda M, Yue J, Shukla R, Guillermier S, Herceg Z, Creveaux M, Accardi R, Tommasino M, Sylla BS.

Mol Cell Biol. 2012 Dec;32(23):4877-90. doi: 10.1128/MCB.01050-12. Epub 2012 Oct 1.

13.

DOK3 negatively regulates LPS responses and endotoxin tolerance.

Peng Q, O'Loughlin JL, Humphrey MB.

PLoS One. 2012;7(6):e39967. doi: 10.1371/journal.pone.0039967. Epub 2012 Jun 27.

14.

TIP30 loss enhances cytoplasmic and nuclear EGFR signaling and promotes lung adenocarcinogenesis in mice.

Li A, Zhang C, Gao S, Chen F, Yang C, Luo R, Xiao H.

Oncogene. 2013 May 2;32(18):2273-81, 2281e.1-12. doi: 10.1038/onc.2012.253. Epub 2012 Jun 25.

15.

A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions.

Xue W, Kitzing T, Roessler S, Zuber J, Krasnitz A, Schultz N, Revill K, Weissmueller S, Rappaport AR, Simon J, Zhang J, Luo W, Hicks J, Zender L, Wang XW, Powers S, Wigler M, Lowe SW.

Proc Natl Acad Sci U S A. 2012 May 22;109(21):8212-7. doi: 10.1073/pnas.1206062109. Epub 2012 May 7.

16.

Integrated analyses of copy number variations and gene expression in lung adenocarcinoma.

Lu TP, Lai LC, Tsai MH, Chen PC, Hsu CP, Lee JM, Hsiao CK, Chuang EY.

PLoS One. 2011;6(9):e24829. doi: 10.1371/journal.pone.0024829. Epub 2011 Sep 14.

17.

Update in lung cancer and oncological disorders 2010.

Halmos B, Powell CA.

Am J Respir Crit Care Med. 2011 Aug 1;184(3):297-302. doi: 10.1164/rccm.201103-0370UP. No abstract available.

18.

Inactivation of the putative suppressor gene DOK1 by promoter hypermethylation in primary human cancers.

Saulnier A, Vaissière T, Yue J, Siouda M, Malfroy M, Accardi R, Creveaux M, Sebastian S, Shahzad N, Gheit T, Hussain I, Torrente M, Maffini FA, Calabrese L, Chiesa F, Cuenin C, Shukla R, Fathallah I, Matos E, Daudt A, Koifman S, Wünsch-Filho V, Menezes AM, Curado MP, Zaridze D, Boffetta P, Brennan P, Tommasino M, Herceg Z, Sylla BS.

Int J Cancer. 2012 Jun 1;130(11):2484-94. doi: 10.1002/ijc.26299. Epub 2011 Sep 22.

19.

The Ras inhibitors caveolin-1 and docking protein 1 activate peroxisome proliferator-activated receptor γ through spatial relocalization at helix 7 of its ligand-binding domain.

Burgermeister E, Friedrich T, Hitkova I, Regel I, Einwächter H, Zimmermann W, Röcken C, Perren A, Wright MB, Schmid RM, Seger R, Ebert MP.

Mol Cell Biol. 2011 Aug;31(16):3497-510. doi: 10.1128/MCB.01421-10. Epub 2011 Jun 20.

20.

Oncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformation.

Janas JA, Van Aelst L.

Mol Cell Biol. 2011 Jul;31(13):2552-65. doi: 10.1128/MCB.05045-11. Epub 2011 May 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk